Loading cancer entity…
Loading cancer entity…
Clinical trials
3,385 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02658929 | Study of bb2121 in Multiple Myeloma | completed | Phase 1 | 67 | CelgeneINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma |
| completed |
| Phase 1 / Phase 2 |
| 226 |
| CelgeneINDUSTRY |
| 4 |
| Dec 13, 2022 |
| clinicaltrials |
| NCT00664898 | A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 18 | Genentech, Inc.INDUSTRY | 0 | Dec 12, 2022 | clinicaltrials |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 16 | Prelude TherapeuticsINDUSTRY | 1 | Nov 15, 2022 | clinicaltrials |
| NCT01575925 | Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)(POM Renal) | completed | Phase 1 | 25 | CelgeneINDUSTRY | 2 | Nov 4, 2022 | clinicaltrials |
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03019666 | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | completed | Phase 1 | 39 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT01380145 | MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | completed | Phase 1 | 13 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01677858 | A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma(CHAMPION 1) | completed | Phase 1 / Phase 2 | 116 | AmgenINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT00784823 | Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma(Mel-Vel) | completed | Phase 1 / Phase 2 | 32 | Hackensack Meridian HealthOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT02384083 | Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients | completed | Phase 1 / Phase 2 | 47 | PETHEMA FoundationOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03650491 | A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | completed | Phase 1 | 31 | Fortis Therapeutics, Inc.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02468687 | NMP in Relapsed / Refractory Myeloma | completed | Phase 1 | 13 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03288480 | A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 24 | Promontory Therapeutics Inc.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT02514668 | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma | completed | Phase 1 | 55 | SanofiINDUSTRY | 3 | Apr 25, 2022 | clinicaltrials |
| NCT03489525 | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma(MEDI2228) | completed | Phase 1 | 107 | MedImmune LLCINDUSTRY | 4 | Mar 28, 2022 | clinicaltrials |
| NCT04163107 | Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma(MYELOMA-HCQ) | completed | Phase 1 | 19 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03464916 | Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04280328 | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 7 | Corvus Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02514239 | Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 2 | Feb 24, 2022 | clinicaltrials |
| NCT01583283 | Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma | completed | Phase 1 | 38 | CelgeneINDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT03111992 | Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | completed | Phase 1 | 26 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 9, 2022 | clinicaltrials |
| NCT01496118 | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04811898 | A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment(LNA-i-miR221) | completed | Phase 1 | 17 | Azienda Ospedaliera Universitaria Mater Domini, CatanzaroOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 84 | Pharmacyclics LLC.INDUSTRY | 2 | Dec 21, 2021 | clinicaltrials |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 91 | MorphoSys AGINDUSTRY | 2 | Nov 16, 2021 | clinicaltrials |
| NCT01038388 | A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 | 30 | Emory UniversityOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT02660281 | URMC Related Haplo-identical Donor BMT(HaploOnly) | completed | Phase 1 | 74 | University of RochesterOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT03263637 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT02646085 | Multiparametric Imaging in Multiple Myeloma | completed | Phase 1 | 10 | Yingbing WangOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03018223 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03958656 | T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2021 | clinicaltrials |
| NCT01965353 | A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma(PanRVD) | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01723020 | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | completed | Phase 1 | 107 | Kartos Therapeutics, Inc.INDUSTRY | 3 | Sep 2, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT02481934 | Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma(NK-VS-MM) | completed | Phase 1 | 5 | Joaquín Martínez López, MD, PhDOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT03383055 | CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig | completed | Phase 1 | 28 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01953692 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | completed | Phase 1 | 197 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 4, 2021 | clinicaltrials |
| NCT01794507 | A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | completed | Phase 1 | 66 | AbbVieINDUSTRY | 3 | Aug 2, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT03665155 | First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT02283775 | SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients(PomdeSAR) | completed | Phase 1 | 54 | SanofiINDUSTRY | 1 | Jul 9, 2021 | clinicaltrials |
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | completed | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2021 | clinicaltrials |
| NCT02569320 | HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 9 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT02609230 | A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma | completed | Phase 1 | 33 | Fox Chase Cancer CenterOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT02129582 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT00858234 | Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) | completed | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 9, 2021 | clinicaltrials |
| NCT02431208 | A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | completed | Phase 1 | 85 | Hoffmann-La RocheINDUSTRY | 1 | Apr 2, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2023source: clinicaltrials